“As part of KBI, Alliance is now able to offer a much broader range of analytical and biophysical characterization services to the biopharmaceutical industry,” Tim Kelly Ph.D., president of KBI Biopharma told Outsourcing-Pharma.com.
The contract development and manufacturing organization’s (CDMO) analytical capabilities in its North Carolina and Colorado facilities include mass spectrometry (Q-TOF and triple TOF), HPLC/UPLC, CE, iCE, ELISA, Biacore, ForteBio, DSF, ICD, FTIR, extensive visible and subvisble particle analyses, among others, Kelly explained.
Moving forward, Alliance and its management team will continue to serve their clients in its San Diego facility and the Alliance name and brand will be retained, Kelly said. Additionally, Dr. Philo and Dr. Arakawa will join KBI’s executive management team and will continue to oversee Alliance operations.
“Scientists in KBI’s NC and CO sites will collaborate with Alliance as needed to perform additional services, and expand the data sets we can provide for comparability and other biopharmaceutical characterization applications,” added Kelly. “We are beginning the integration process to enhance the value that KBI and Alliance can deliver to our client partners.”
The announcement follows previous expansions in 2017, including the acquisition of Opexa’s cGMP cell therapy manufacturing facility in February, and more recently, plans to expand sites in in Durham, NC and Boulder, CO.
Additionally, KBI’s parent company, JSR Life Sciences, is set to acquire Selexis SA, which will be integrated with KBI.